Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus standard of care for major depressive disorder with imminent suicide risk
2016-003992-23Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started May 2017; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2016-003992-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003992-23.